<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004825</url>
  </required_header>
  <id_info>
    <org_study_id>199/13283</org_study_id>
    <secondary_id>CHP-FDR001181-ST</secondary_id>
    <nct_id>NCT00004825</nct_id>
  </id_info>
  <brief_title>Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>FDA Office of Orphan Products Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor&#xD;
      I (IGF-I) on insulin secretion in children with hyperinsulinism.&#xD;
&#xD;
      II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this&#xD;
      patient population.&#xD;
&#xD;
      III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other&#xD;
      insulin dependent parameters, in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Octreotide and/or diazoxide are discontinued on day 1, and fasting blood&#xD;
      glucose is monitored. Patients receive test meals of Sustacal on days 3 and 4 and are&#xD;
      assessed for insulin response.&#xD;
&#xD;
      Beginning on day 5, patients are given recombinant human insulin-like growth factor I&#xD;
      subcutaneously every 12 hours for a total of 3 doses. The first dose (on day 5) is given 30&#xD;
      minutes before a Sustacal challenge, the second dose is followed by a bedtime snack, and the&#xD;
      third dose (on day 6) is followed by a supervised fast.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1998</start_date>
  <completion_date>May 1998</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>10</enrollment>
  <condition>Hyperinsulinism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human insulin-like growth factor I</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Diagnosis of hyperinsulinism (i.e. evidence of fasting hypoglycemia with inadequate&#xD;
        suppression of insulin, normal pituitary and adrenal function, and increased insulin&#xD;
        action)&#xD;
&#xD;
        Suboptimal control of blood sugar (i.e. inability to fast at least 10 hours with a blood&#xD;
        sugar of 60 mg/dL or greater)&#xD;
&#xD;
        No suspected insulinoma&#xD;
&#xD;
        Must be currently managed on a regimen of diazoxide, octreotide and/or frequent feedings to&#xD;
        control hypoglycemia&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        See Disease Characteristics&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Hematopoietic: No anemia or other concerns of blood volume depletion&#xD;
&#xD;
        Renal: No renal dysfunction&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No known malignancy&#xD;
&#xD;
          -  No other major medical conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pinchas Cohen</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <verification_date>July 1998</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>endocrine disorders</keyword>
  <keyword>hyperinsulinism</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperinsulinism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Mitogens</mesh_term>
    <mesh_term>Mecasermin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

